{ "company": "Danaher Corporation", "ticker": "DHR", "period": { "from": "2026-03-22", "to": "2026-04-21", "days": 30 }, "sentiment_breakdown": { "positive": 42, "negative": 18, "neutral": 27 }, "synthesis": { "executive_summary": "Sentiment analysis for Danaher Corporation (DHR) from 2026-03-22 to 2026-04-21. Analyzed 87 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "Cell Line Development Market to Reach $8.95 Bn by 2031 with Gene & Cell Therapy Manufacturing Growing at 10.88% CAGR, Says Mordor Intelligence", "date": "2026-04-14", "source": "news", "score": 0.958 }, { "title": "Global Metabolomics Market Poised for Strong Growth as Advancements in Precision Medicine and Biomarker Discovery Accelerate Adoption: Verified Market Research®", "date": "2026-04-10", "source": "news", "score": 0.951 }, { "title": "Mastering DHF, DMR & DHR Course: Essential FDA Documentation for Medical Devices (ONLINE AND ON-DEMAND: May 14, 2026)", "date": "2026-04-15", "source": "news", "score": 0.9 }, { "title": "Danaher (DHR) Projects 2026 Revenue Growth at TD Cowen 46th Annual Health Care Conference", "date": "2026-03-24", "source": "news", "score": 0.9 }, { "title": "Dengue Testing Market Size to be Valued at USD 971.11 Million by 2035; Industry Growth is Driven by the Increase in Dengue Cases in Tropical and Sub-tropical Nations Globally | SNS Insider", "date": "2026-04-20", "source": "news", "score": 0.863 }, { "title": "[Latest] Global Environmental Mass Spectrometry Market Size/Share Worth USD 6.47 Billion by 2035 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)", "date": "2026-04-02", "source": "news", "score": 0.859 }, { "title": "Wealth Enhancement Trust Services Inc. Buys Shares of 14,087 Danaher Corporation $DHR", "date": "2026-04-19", "source": "alpha_vantage", "score": 0.827 }, { "title": "Cell Therapy Technology Market Research and Global Forecast Report 2025-2030: Rising Chronic Disease Burden and CRISPR-Driven Gene Editing Innovations Driving Growth", "date": "2026-04-13", "source": "news", "score": 0.772 }, { "title": "AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages", "date": "2026-04-09", "source": "news", "score": 0.751 }, { "title": "Flow Cytometry Market Set to Surpass USD 12.19 Billion by 2035, Driven by Rising Demand for Precision Diagnostics – SNS Insider", "date": "2026-04-08", "source": "news", "score": 0.718 } ], "top_negative": [ { "title": "What May (or May Not) Get University Employees Fired", "date": "2026-04-03", "source": "news", "score": -0.896 }, { "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider", "date": "2026-04-13", "source": "news", "score": -0.869 }, { "title": "Any Other Business: Fail to prepare, prepare to be well charged by a PR guru", "date": "2026-04-12", "source": "news", "score": -0.67 }, { "title": "Mondraker Leaves Something to the Imagination with Early Tease of Avinox-Powered ZENDIT eMTB", "date": "2026-03-27", "source": "news", "score": -0.557 }, { "title": "Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Research and Global Forecast Report 2026-2035", "date": "2026-04-14", "source": "news", "score": -0.542 }, { "title": "Longer duration of amenorrhea is associated with lower delay discounting and less hedonic eating in girls and young women with low-weight eating disorders.", "date": "2026 Apr 3", "source": "pubmed", "score": -0.542 }, { "title": "Purvalanol A (CDK Inhibitor) Market Report 2026: Expanding Molecular Biology and Cancer Research Fuelling Market Growth", "date": "2026-04-07", "source": "news", "score": -0.527 }, { "title": "India launches first study on nutrition, supplements for adolescent athletes - The Tribune", "date": "2026-04-12", "source": "news", "score": -0.509 }, { "title": "Danaher Gears Up to Post Q1 Earnings: What Lies Ahead for the Stock?", "date": "2026-04-16", "source": "alpha_vantage", "score": -0.421 }, { "title": "Danaher Gears Up to Post Q1 Earnings: What Lies Ahead for the Stock?", "date": "2026-04-16", "source": "alpha_vantage", "score": -0.421 } ], "raw_data": { "total_items": 87, "items": [ { "source": "alpha_vantage", "title": "Duncker Streett & Co. Inc. Increases Position in Danaher Corporation $DHR", "url": "https://www.marketbeat.com/instant-alerts/filing-duncker-streett-co-inc-increases-position-in-danaher-corporation-dhr-2026-04-21/", "date": "2026-04-21", "summary": "Duncker Streett & Co. Inc. increased its stake in Danaher Corporation by 20.4% in the fourth quarter of the previous year, now holding 58,047 shares valued at $13.29 million. Danaher recently raised its quarterly dividend to $0.40 per share and exceeded quarterly EPS and revenue expectations. Analysts currently maintain a \"Moderate Buy\" consensus rating for the stock with an average target price of $246.50.", "sentiment_score": 0.419413, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Assessing Thermo Fisher Scientific (TMO) Valuation After New PCR Launch And Data Partnerships", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/assessing-thermo-fisher-scientific-tmo-valuation-after-new-p", "date": "2026-04-21", "summary": "Thermo Fisher Scientific (TMO) has introduced a new PCR instrument and formed data-driven partnerships, leading to mixed stock performance. While the company's valuation is considered 2.6% undervalued at $540.27 according to one narrative, future growth depends on R&D budgets, successful M&A integration, and demand for its tools. Investors are advised to consider the full picture, including potential risks, before making investment decisions.", "sentiment_score": 0.15626, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.616582, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock (US76155R1086): Is its life sciences focus strong enough to drive steady investor", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/revvity-inc-stock-us76155r1086-is-its-life-sciences-focus-strong/69223498", "date": "2026-04-21", "summary": "Revvity Inc. (US76155R1086) provides tools for drug discovery and diagnostics, positioning it in the life sciences sector with robust demand. The company's core business model focuses on precision tools for research and diagnostics, emphasizing recurring revenue from consumables and services. Revvity aims for long-term growth through strategic investments in high-growth areas like cell and gene therapy, digital integration, and global expansion, while facing risks from biopharma budget cuts and ", "sentiment_score": 0.106912, "sentiment_label": "Neutral", "relevance_score": 0.565548, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "CVRx (CVRX) details 2026 virtual meeting, board nominees and pay", "url": "https://www.stocktitan.net/sec-filings/CVRX/def-14a-cv-rx-inc-definitive-proxy-statement-1faf36dcc47e.html", "date": "2026-04-20", "summary": "CVRx, Inc. will hold its 2026 annual shareholder meeting virtually on June 1, 2026, where stockholders will vote on the election of three Class II directors, including CEO Kevin Hykes and new nominee Michael Dale, and the ratification of Grant Thornton as the independent auditor. The company is set to lose its \"emerging growth company\" status by December 31, 2026, which will lead to increased reporting requirements. The proxy statement also details executive and director compensation, with CEO K", "sentiment_score": 0.089667, "sentiment_label": "Neutral", "relevance_score": 0.610897, "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "VLTO: Strong Fundamentals, but Growth Concerns Keep Outlook Balanced", "url": "https://www.tradingview.com/news/zacks:4d72d256e094b:0-vlto-strong-fundamentals-but-growth-concerns-keep-outlook-balanced/", "date": "2026-04-20", "summary": "Veralto (VLTO) presents a balanced investment case, boasting strong positions in water quality and product inspection, and a robust financial standing. However, its modest growth expectations, competitive landscape, and stock volatility suggest a cautious \"wait-and-see\" approach for investors. Despite solid fundamentals and strategic acquisitions, growth concerns and competitive pressures temper its outlook, earning it a Zacks Rank #3 (Hold).", "sentiment_score": 0.115426, "sentiment_label": "Neutral", "relevance_score": 0.635395, "sentiment": { "label": "positive", "score": 0.676, "confidence": 0.68 } }, { "source": "alpha_vantage", "title": "Danaher Corp. stock (US2358511028): Is its life sciences dominance strong enough to unlock new upsid", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/danaher-corp-stock-us2358511028-is-its-life-sciences-dominance-strong/69219197", "date": "2026-04-20", "summary": "Danaher operates as a science and technology leader focused on life sciences, diagnostics, and environmental solutions, utilizing an acquisition strategy to drive growth. The company's diverse portfolio and strategic initiatives like significant R&D investment and continuous improvement through its DPS operating system position it as a resilient investment amidst industry shifts. Despite potential risks like R&D budget cuts and competitive threats, analysts maintain a positive outlook due to Dan", "sentiment_score": 0.455466, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "alpha_vantage", "title": "Integrated DNA Technologies Expands Coralville Manufacturing Footprint to Support Growing Global Demand for MRD Solutions", "url": "https://www.voiceofalexandria.com/news/national_business_news/integrated-dna-technologies-expands-coralville-manufacturing-footprint-to-support-growing-global-demand-for-mrd-solutions/article_59490908-b46c-59d1-a527-1f74fe80ad9c.html", "date": "2026-04-20", "summary": "Integrated DNA Technologies (IDT) has expanded its manufacturing facility in Coralville, Iowa, significantly increasing its synthesis capacity to support the growing global demand for minimal residual disease (MRD) solutions and next-generation sequencing (NGS)-based oncology workflows. This expansion enables faster, more scalable production of high-quality, customizable oligonucleotides crucial for cancer research and clinical diagnostics. The investment also reinforces IDT's leadership in MRD ", "sentiment_score": 0.344111, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.926871, "sentiment": { "label": "positive", "score": 0.612, "confidence": 0.61 } }, { "source": "alpha_vantage", "title": "DHR Q1'26 Earnings: EPS estimate is 1.94 USD", "url": "https://www.tradingview.com/news/tradingview:21f09841212a1:0-dhr-q1-26-earnings-eps-estimate-is-1-94-usd/", "date": "2026-04-20", "summary": "Danaher Corporation (DHR) is scheduled to release its Q1'26 earnings on April 21st, after the market closes, at 6:00 AM ET (10:00 AM UTC). Analysts estimate a revenue of 5.99 billion USD and an EPS of 1.94 USD for the quarter. The article also provides a historical table of reported and estimated revenue and EPS, along with surprise percentages, for previous quarters.", "sentiment_score": 0.226267, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "A Look At Vontier (VNT) Valuation After Adding Denice Biocca As Chief People Officer", "url": "https://simplywall.st/stocks/us/tech/nyse-vnt/vontier/news/a-look-at-vontier-vnt-valuation-after-adding-denice-biocca-a", "date": "2026-04-20", "summary": "Vontier (VNT) recently appointed Denice Biocca as Chief People Officer, drawing fresh investor attention just before its upcoming earnings. The company's stock currently trades at US$37.30, showing positive momentum despite a slight year-to-date decline; however, a widely followed narrative suggests its fair value is around $54.08, implying it is undervalued. This valuation is based on specific growth, margin, and discount rate assumptions, but potential risks such as sluggish core revenue growt", "sentiment_score": 0.105667, "sentiment_label": "Neutral", "relevance_score": 0.640734, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Fortive Corp stock (US34959J1088): Why Google Discover changes matter more now", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortive-corp-stock-us34959j1088-why-google-discover-changes-matter-more/69214910", "date": "2026-04-20", "summary": "The article explains how Google's 2026 Discover Core Update is revolutionizing access to insights on Fortive Corp (NYSE:FTV) stock for investors. This update proactively delivers personalized mobile content on industrial tech trends, acquisitions, and precision instrument growth, removing the need for manual searches. It emphasizes the importance of mobile-optimized, credible content, enabling faster decision-making for investors following industrial stocks.", "sentiment_score": 0.129444, "sentiment_label": "Neutral", "relevance_score": 0.701327, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Chromatograph (Labor): Precision Tools Drive Agilent's Lab Market Edge", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/chromatograph-labor-precision-tools-drive-agilent-s-lab-market-edge/69211472", "date": "2026-04-20", "summary": "Agilent Technologies' chromatographs are crucial for precision in drug testing and research, driving the company's growth amidst increasing biotech demands. The article highlights Agilent's competitive edge through innovative chromatography systems, strategic investments in AI-driven analysis, and expansion into emerging markets. Despite competition and supply chain risks, Agilent maintains a strong market position due to its reliable technology, recurring revenue from consumables, and robust gl", "sentiment_score": 0.221723, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.568676, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Danaher (DHR) Q1 Earnings: What To Expect", "url": "https://www.financialcontent.com/article/stockstory-2026-4-20-danaher-dhr-q1-earnings-what-to-expect", "date": "2026-04-19", "summary": "Danaher (DHR) is set to announce its Q1 earnings this Tuesday before market open. Analysts expect a 4.5% year-on-year revenue growth for the diversified science and technology company, improving from flat revenue in the same quarter last year. The company has a history of exceeding Wall Street's expectations, and investor sentiment for life sciences tools & services stocks has been positive recently.", "sentiment_score": 0.145956, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Chromatograph (Labor): Advances in Tech Boost Agilent's Lab Market Edge", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/chromatograph-labor-advances-in-tech-boost-agilent-s-lab-market-edge/69208094", "date": "2026-04-19", "summary": "Agilent Technologies' chromatography tools are crucial for precise lab analysis in biotech and pharma. The company's focus on innovation, sustainability, and software integration helps it maintain a competitive edge despite market challenges and rivals. This strategic positioning, coupled with increasing demand from biopharma and environmental sectors, indicates a strong outlook for Agilent's stock.", "sentiment_score": 0.210664, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.551384, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Is Cheaper Energy and Shipping Altering The Investment Case For Charles River Laboratories (CRL)?", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/is-cheaper-energy-and-shipping-altering-the-investment-case", "date": "2026-04-19", "summary": "The reopening of the Strait of Hormuz has led to reduced global logistics and energy costs, which could benefit Charles River Laboratories International by easing operating conditions and supporting margins for its research and lab services. While helpful, these cost reductions are not considered \"game-changing,\" and the company still faces risks from demand softness and cancellations in longer-duration studies. Investors will closely watch the upcoming Q1 2026 results for insights into how thes", "sentiment_score": 0.116802, "sentiment_label": "Neutral", "relevance_score": 0.63782, "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "Wealth Enhancement Trust Services Inc. Buys Shares of 14,087 Danaher Corporation $DHR", "url": "https://www.marketbeat.com/instant-alerts/filing-wealth-enhancement-trust-services-inc-buys-shares-of-14087-danaher-corporation-dhr-2026-04-19/", "date": "2026-04-19", "summary": "Wealth Enhancement Trust Services Inc. recently acquired 14,087 shares of Danaher Corporation (NYSE:DHR) valued at approximately $3.225 million during the fourth quarter. This acquisition is part of a broader trend, as several other institutional investors and hedge funds have also significantly increased their holdings in Danaher. The company last reported strong quarterly earnings, beating analyst estimates, and recently announced an increased quarterly dividend.", "sentiment_score": 0.389254, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.827, "confidence": 0.83 } }, { "source": "alpha_vantage", "title": "Ninety One UK Ltd Sells 12,023 Shares of Danaher Corporation $DHR", "url": "https://www.marketbeat.com/instant-alerts/filing-ninety-one-uk-ltd-sells-12023-shares-of-danaher-corporation-dhr-2026-04-19/", "date": "2026-04-19", "summary": "Ninety One UK Ltd reduced its stake in Danaher Corporation by 26.7%, selling 12,023 shares and retaining 33,088 shares valued at $7.58 million. Institutional investors collectively own about 79.1% of Danaher's stock, while company insiders hold 10.8%. Danaher recently raised its quarterly dividend to $0.40, announced quarterly earnings that exceeded estimates, and has a consensus \"Moderate Buy\" rating from analysts with a price target of $246.50.", "sentiment_score": 0.136523, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Repligen Corp stock (US7607591002): Is its bioprocessing dominance strong enough to unlock new upside?", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/repligen-corp-stock-us7607591002-is-its-bioprocessing-dominance-strong/69191151", "date": "2026-04-19", "summary": "Repligen Corp (US7607591002) is a leader in bioprocessing tools, essential for the manufacturing of biologics, offering investors targeted exposure to life sciences growth without the direct risks of drug development. The company specializes in consumables, systems, and services for filtration, chromatography, and process analytics, benefiting from a recurring revenue model due to the repeated necessity of its products in biologic drug production. Analysts generally view Repligen positively, hig", "sentiment_score": 0.232979, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.603225, "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "alpha_vantage", "title": "Danaher Corporation $DHR Shares Bought by Merit Financial Group LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-danaher-corporation-dhr-shares-bought-by-merit-financial-group-llc-2026-04-19/", "date": "2026-04-19", "summary": "Merit Financial Group LLC significantly increased its stake in Danaher Corporation (DHR) by 32.6% in the fourth quarter, bringing its total holdings to 27,400 shares valued at over $6.27 million. Institutional investors now own about 79.05% of Danaher, reflecting broad investor confidence. The company also reported strong quarterly earnings, beating EPS expectations and showing a 4.6% year-over-year revenue increase, leading to a raised quarterly dividend.", "sentiment_score": 0.431688, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.612, "confidence": 0.61 } }, { "source": "alpha_vantage", "title": "Apple Prevails in ITC Dispute with Masimo Over Watch Patents - News and Statistics", "url": "https://www.indexbox.io/blog/apple-wins-itc-case-over-watch-blood-oxygen-technology/", "date": "2026-04-19", "summary": "The U.S. International Trade Commission (ITC) has ruled in favor of Apple in a patent dispute with Masimo concerning blood-oxygen measurement technology in Apple Watches. The ITC declined to review a prior ruling that found Apple's redesigned watches do not infringe Masimo's patents, allowing Apple to continue offering the health feature. Masimo, owned by Danaher, still retains the right to appeal and has ongoing separate legal actions against Apple regarding patent and trade-secret infringement", "sentiment_score": 0.123916, "sentiment_label": "Neutral", "relevance_score": 0.73608, "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Agilent Stock Performance & Valuation Analysis 2026 | Business Review - News and Statistics", "url": "https://www.indexbox.io/blog/agilent-stock-analysis-6-month-decline-and-business-performance-review/", "date": "2026-04-18", "summary": "Agilent's stock price has declined by 16.7% over the past six months to $118.28, underperforming the S&P 500. The company's annualized revenue growth over five years was 5%, with organic revenue growth at 4.2% over two years, both considered mediocre. While the stock's current valuation is deemed reasonable with a forward P/E of 19.5, its business performance does not meet certain quality thresholds, suggesting better investment alternatives may exist.", "sentiment_score": 0.123088, "sentiment_label": "Neutral", "relevance_score": 0.613016, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Barclays and Evercore Stay Positive on Danaher (DHR) Despite Cutting Price Targets", "url": "https://www.insidermonkey.com/blog/barclays-and-evercore-stay-positive-on-danaher-dhr-despite-cutting-price-targets-1740799/", "date": "2026-04-18", "summary": "Barclays and Evercore ISI have maintained positive ratings on Danaher Corporation (DHR) despite both firms cutting their price targets for the life sciences and diagnostics company. Barclays reduced its target from $250 to $230 while maintaining an Overweight rating, noting sector risks but supporting a \"last-cut thesis.\" Evercore ISI cut its target from $254 to $225, kept an Outperform rating, and added DHR to its \"Tactical Outperform\" list as part of Q1 previews.", "sentiment_score": 0.141106, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.609, "confidence": 0.61 } }, { "source": "alpha_vantage", "title": "Graco Inc stock (US3841091040): Why its fluid management leadership matters more now for investors", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/graco-inc-stock-us3841091040-why-its-fluid-management-leadership/69191204", "date": "2026-04-18", "summary": "Graco Inc. (US3841091040) specializes in fluid handling equipment, serving industries like construction, manufacturing, and process with products ranging from paint sprayers to lubrication systems. The company boasts a strong financial profile with consistent free cash flow, a track record of dividend growth (20+ years), minimal debt, and high returns on invested capital. Graco's competitive advantages stem from its engineering prowess, global footprint, and focus on innovation within high-deman", "sentiment_score": 0.109859, "sentiment_label": "Neutral", "relevance_score": 0.553216, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Repligen Corp stock (US7607591002): Is its bioprocessing dominance strong enough to unlock new upside?", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/repligen-corp-stock-us7607591002-is-its-bioprocessing-dominance-strong/69191151", "date": "2026-04-18", "summary": "Repligen Corp is a leader in bioprocessing tools, essential for the efficient production of biologics. The company's specialized technologies and recurring revenue model position it for growth in the expanding biotech manufacturing market. Investors can gain targeted exposure to life sciences innovation without direct drug development risks, supported by Repligen's strategic initiatives and strong competitive position.", "sentiment_score": 0.12928, "sentiment_label": "Neutral", "relevance_score": 0.581229, "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "alpha_vantage", "title": "Mirae Asset Global Investments Co. Ltd. Grows Holdings in Danaher Corporation $DHR", "url": "https://www.marketbeat.com/instant-alerts/filing-mirae-asset-global-investments-co-ltd-grows-holdings-in-danaher-corporation-dhr-2026-04-18/", "date": "2026-04-18", "summary": "Mirae Asset Global Investments Co. Ltd. significantly increased its stake in Danaher Corporation by 41.8% in Q4, now holding 168,163 shares valued at approximately $38.5 million. This aligns with other institutional investors also growing their positions, collectively holding about 79% of the stock. Danaher also reported strong Q4 earnings, surpassing analyst estimates, and increased its quarterly dividend to $0.40 per share, while analysts maintain a \"Moderate Buy\" rating with an average price ", "sentiment_score": 0.496521, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?", "url": "https://www.easternprogress.com/did-danaher-corporation-insiders-breach-their-fiduciary-duties-to-shareholders/article_0cf071a0-5c71-5d24-a978-aaf1309b1756.html", "date": "2026-04-18", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Danaher Corporation (NYSE: DHR) breached their fiduciary duties to shareholders. The firm encourages long-term Danaher shareholders to come forward to discuss potential corporate governance reforms, the return of funds to the company, or other legal relief. Shareholder involvement is emphasized as a way to improve company policies and enhance shareholder value.", "sentiment_score": -0.424152, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Avantor Inc stock (US05352A1007): Why its life sciences leadership matters more now for investors", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/avantor-inc-stock-us05352a1007-why-its-life-sciences-leadership-matters/69189281", "date": "2026-04-18", "summary": "Avantor Inc. is a crucial supplier of products and services to the global life sciences and biopharma industries, positioning it well in high-growth sectors like gene therapy and drug development. The company's business model emphasizes recurring revenue from consumables, operational efficiencies, and a disciplined acquisition strategy, providing stability and growth potential for investors. Avantor's commitment to sustainability and its response to rising biopharma R&D spending further strength", "sentiment_score": 0.107208, "sentiment_label": "Neutral", "relevance_score": 0.559676, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Danaher Corporation (NYSE:DHR) Given Consensus Rating of \"Moderate Buy\" by Brokerages", "url": "https://www.marketbeat.com/instant-alerts/danaher-corporation-nysedhr-given-consensus-rating-of-moderate-buy-by-brokerages-2026-04-18/", "date": "2026-04-18", "summary": "Danaher Corporation (NYSE:DHR) has received a \"Moderate Buy\" consensus rating from 21 brokerages, with an average 12-month price target of $246.50, suggesting significant upside from its current price. The company recently reported strong quarterly results, beating EPS and revenue estimates, and increased its quarterly dividend to $0.40. Insider activity showed an EVP selling shares, while institutional investors have been increasing their holdings.", "sentiment_score": 0.429035, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Apple secures a win as US trade tribunal rejects Masimo’s bid for new watch ban", "url": "https://www.investing.com/news/company-news/apple-secures-a-win-as-us-trade-tribunal-rejects-masimos-bid-for-new-watch-ban-4622095", "date": "2026-04-18", "summary": "Apple has successfully defended against Masimo's attempt to block imports of its smartwatches, as a U.S. trade tribunal ruled that Apple's redesigned devices do not infringe on Masimo’s patents. The U.S. International Trade Commission (ITC) closed the case after declining to review a preliminary ruling that found Apple's updated blood-oxygen monitoring technology did not violate Masimo’s intellectual property. Despite this victory, Apple remains in ongoing legal disputes with Masimo, including a", "sentiment_score": -0.116548, "sentiment_label": "Neutral", "relevance_score": 0.612121, "sentiment": { "label": "negative", "score": -0.178, "confidence": 0.18 } }, { "source": "alpha_vantage", "title": "Apple Clears Major Legal Hurdle After U.S. Trade Tribunal Shuts Down Masimo’s Latest Watch Ban Attempt", "url": "https://stocktwits.com/news-articles/markets/equity/apple-clears-major-legal-hurdle-after-us-trade-tribunal-shuts-down-masimos-latest-watch-ban-attempt/cZJ6WUSRIUr", "date": "2026-04-17", "summary": "The U.S. International Trade Commission (ITC) has ruled in favor of Apple, rejecting Masimo’s attempt to impose a new import ban on certain Apple Watch models. This decision follows a preliminary ruling in March that found Apple's redesigned smartwatches do not infringe Masimo's blood-oxygen measurement patents. Masimo, which had accused Apple of intellectual property theft, can appeal the ITC's decision.", "sentiment_score": 0.097786, "sentiment_label": "Neutral", "relevance_score": 0.708796, "sentiment": { "label": "negative", "score": -0.363, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "Fortive Corp. stock (US34959J1088): Why does its industrial tech edge matter more now for U.S. inves", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/fortive-corp-stock-us34959j1088-why-does-its-industrial-tech-edge/69184718", "date": "2026-04-17", "summary": "Fortive Corp. (US34959J1088) is positioned for growth due to its focus on industrial technology and automation, delivering precision tools and sensors. The company's business model emphasizes high-margin, recurring revenue from software-enabled hardware in essential industries like manufacturing and healthcare. Amid accelerating industrial automation and AI infrastructure buildout, Fortive offers U.S. investors a resilient option with defensive growth characteristics and a strong competitive moa", "sentiment_score": 0.322168, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.625922, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Energy Vault (NYSE: NRGV) details 2026 virtual meeting, board and pay", "url": "https://www.stocktitan.net/sec-filings/NRGV/def-14a-energy-vault-holdings-inc-definitive-proxy-statement-dd0f5acf5521.html", "date": "2026-04-17", "summary": "Energy Vault Holdings, Inc. (NYSE: NRGV) will hold a virtual annual meeting on May 29, 2026, for stockholders of record as of March 31, 2026. Key proposals include electing three Class II directors and ratifying BDO USA, P.C. as the independent auditor for 2026. The proxy statement details executive compensation for Robert Piconi, Michael Beer, and Akshay Ladwa, including salaries, bonuses, and equity awards, and outlines the company's corporate governance, risk oversight, and related party tran", "sentiment_score": 0.143508, "sentiment_label": "Neutral", "relevance_score": 0.610842, "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "alpha_vantage", "title": "Bio-Techne Corp. stock underperforms Wednesday when compared to competitors", "url": "https://www.msn.com/en-us/money/topstocks/bio-techne-corp-stock-underperforms-wednesday-when-compared-to-competitors/ar-AA1EMLEy?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-04-17", "summary": "Bio-Techne Corp. (TECH) stock closed lower on Wednesday, underperforming its competitors and the broader market. Despite the daily loss, the stock remains above its 52-week low.", "sentiment_score": -0.125277, "sentiment_label": "Neutral", "relevance_score": 0.709043, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Danaher Corporation $DHR Stake Lifted by Whittier Trust Co.", "url": "https://www.marketbeat.com/instant-alerts/filing-danaher-corporation-dhr-stake-lifted-by-whittier-trust-co-2026-04-17/", "date": "2026-04-17", "summary": "Whittier Trust Co. significantly increased its stake in Danaher Corporation (DHR) by", "sentiment_score": 0.410757, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "DHR Maintained by Baird -- Price Target Lowered to $249", "url": "https://www.gurufocus.com/news/8800466/dhr-maintained-by-baird-price-target-lowered-to-249", "date": "2026-04-17", "summary": "Baird has maintained its \"Outperform\" rating for Danaher Corp (DHR) but lowered its price target slightly from $251 to $249. Despite the reduced price target, GuruFocus indicates DHR is undervalued by 17.6% with a strong GF Score™ of 80, suggesting solid fundamentals. However, the article notes recent insider selling and a higher P/E ratio compared to its historical median, which warrant careful consideration by investors.", "sentiment_score": 0.138607, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Danaher and AstraZeneca to develop diagnostic tools and tests", "url": "http://www.msn.com/en-us/health/medical/danaher-and-astrazeneca-to-develop-diagnostic-tools-and-tests/ar-AA1FO2iD?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-04-17", "summary": "Danaher and AstraZeneca have partnered to develop new diagnostic tools and tests. This collaboration aims to provide innovative solutions to improve disease detection and patient stratification. The companies will leverage their respective expertise in diagnostics and drug development to achieve their goals.", "sentiment_score": 0.307636, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.981723, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Danaher (NYSE: DHR) secures $5B 364-day revolving credit facility", "url": "https://www.stocktitan.net/sec-filings/DHR/8-k-danaher-corp-de-reports-material-event-b16bc83f3a31.html", "date": "2026-04-17", "summary": "Danaher Corporation has secured a new $5 billion 364-day revolving credit facility with Bank of America, N.A., expiring on April 15, 2027. This facility provides liquidity support for its U.S. dollar commercial paper program and general corporate purposes, with interest rates and fees dependent on Danaher's long-term debt credit rating and a covenant requiring a Consolidated Leverage Ratio of 0.65 to 1.00 or less.", "sentiment_score": 0.128039, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.599, "confidence": 0.6 } }, { "source": "alpha_vantage", "title": "KBC Group NV Has $65.13 Million Stock Holdings in Danaher Corporation $DHR", "url": "https://www.marketbeat.com/instant-alerts/filing-kbc-group-nv-has-6513-million-stock-holdings-in-danaher-corporation-dhr-2026-04-17/", "date": "2026-04-17", "summary": "KBC Group NV increased its stake in Danaher Corporation (DHR) by 6.9% in the fourth quarter, now holding 284,495 shares valued at $65.13 million. Danaher recently reported strong quarterly earnings, beating analyst estimates with an EPS of $2.23 and revenue of $6.84 billion, and raised its quarterly dividend to $0.40 per share. The stock maintains a \"Moderate Buy\" consensus rating from analysts, with a target price of $247.35, despite recent stock price fluctuations.", "sentiment_score": 0.327774, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Lbp Am Sa Purchases 46,347 Shares of Danaher Corporation $DHR", "url": "https://www.marketbeat.com/instant-alerts/filing-lbp-am-sa-purchases-46347-shares-of-danaher-corporation-dhr-2026-04-17/", "date": "2026-04-17", "summary": "Lbp Am Sa significantly increased its stake in Danaher Corporation (NYSE:DHR) during the fourth quarter, purchasing an additional 46,347 shares, bringing its total holdings to 57,309 shares valued at $13.119 million. Other institutional investors also adjusted their positions in Danaher, which has a \"Moderate Buy\" consensus rating and a consensus price target of $247.35 from Wall Street analysts. The company recently reported strong earnings, beating analyst estimates, and increased its quarterl", "sentiment_score": 0.252165, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Bioprocessing: the hidden engine accelerating advances in our health", "url": "https://www.danaher.com/bioprocessing-hidden-engine-accelerating-advances-our-health", "date": "2026-04-16", "summary": "Bioprocessing, though not widely understood, is crucial for producing life-changing biologic medicines like monoclonal antibodies, gene therapies, and cell therapies. While scientific discovery is accelerating, manufacturing capabilities struggle to keep pace due to the complexity and sensitivity of biologic production, creating constraints in patient access and affordability. Overcoming these challenges requires continuous innovation in process technologies, digital systems, resilient supply ch", "sentiment_score": 0.48804, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Danaher Corporation (NYSE:DHR) Short Interest Up 25.0% in March", "url": "https://www.marketbeat.com/instant-alerts/danaher-corporation-nysedhr-short-interest-up-250-in-march-2026-04-16/", "date": "2026-04-16", "summary": "Danaher Corporation (NYSE:DHR) experienced a 25.0% increase in short interest in March, reaching 6,939,368 shares, which represents 1.1% of its shares short and a short-interest ratio of 1.6 days. The company recently increased its quarterly dividend to $0.40, payable on April 24th, resulting in an annualized dividend of $1.60 and a 0.8% yield. Danaher's Q earnings surpassed expectations with EPS of $2.23 and revenue of $6.84 billion, while analysts maintain a \"Moderate Buy\" consensus with an av", "sentiment_score": 0.185924, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Danaher Corp. stock outperforms competitors despite losses on the day", "url": "https://www.marketwatch.com/data-news/danaher-corp-stock-outperforms-competitors-despite-losses-on-the-day-f53e2f8e-c4e40384f9dd", "date": "2026-04-16", "summary": "Danaher Corp. shares (DHR) fell by 2.20% to $193.78 on Thursday, marking its second consecutive day of losses. Despite this decline, the stock still outperformed the broader market, as the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) both saw gains.", "sentiment_score": -0.218255, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.309, "confidence": 0.31 } }, { "source": "alpha_vantage", "title": "Is Evotec (XTRA:EVT) Quietly Redefining Its Operating Model With Horizon And A New COO?", "url": "https://simplywall.st/stocks/de/pharmaceuticals-biotech/etr-evt/evotec-shares/news/is-evotec-xtraevt-quietly-redefining-its-operating-model-wit", "date": "2026-04-16", "summary": "Evotec SE has reported its 2025 results with sales of €788.37 million and a reduced net loss, while simultaneously advancing its Horizon restructuring program. The appointment of Dr. Ingrid Müller as COO is expected to drive global operations and the Horizon initiative, focusing on improved execution and operational efficiency. This leadership change and restructuring aims to reshape Evotec's investment narrative, with projected revenue growth and a €6.92 fair value by 2029.", "sentiment_score": 0.147959, "sentiment_label": "Neutral", "relevance_score": 0.605554, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Danaher Gears Up to Post Q1 Earnings: What Lies Ahead for the Stock?", "url": "https://sg.finance.yahoo.com/news/danaher-gears-post-q1-earnings-144800880.html", "date": "2026-04-16", "summary": "Danaher Corporation (DHR) is set to announce its first-quarter 2026 earnings on April 21, with Zacks Consensus Estimates predicting a revenue increase of 4.4% and an earnings per share rise of 3.2% year-over-year. Key growth drivers include strength in its bioprocessing, diagnostics, and life sciences segments, buoyed by increased demand and strategic acquisitions like Abcam plc. However, rising operating costs, input costs, product mix changes, and foreign currency headwinds could impact profit", "sentiment_score": 0.110369, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "Danaher Gears Up to Post Q1 Earnings: What Lies Ahead for the Stock?", "url": "https://www.tradingview.com/news/zacks:a9aaabf8e094b:0-danaher-gears-up-to-post-q1-earnings-what-lies-ahead-for-the-stock/", "date": "2026-04-16", "summary": "Danaher (DHR) is set to release its Q1 2026 earnings on April 21st, with Zacks Consensus Estimates projecting revenue growth of 4.4% and an EPS increase of 3.2%. The company's bioprocessing, molecular diagnostics, and life sciences segments are expected to drive growth, partially offset by rising costs and foreign currency headwinds. Danaher's earnings model, however, does not conclusively predict a beat for this quarter.", "sentiment_score": 0.137999, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "Greenwood Capital Associates LLC Has $5.01 Million Stake in Danaher Corporation $DHR", "url": "https://www.marketbeat.com/instant-alerts/filing-greenwood-capital-associates-llc-has-501-million-stake-in-danaher-corporation-dhr-2026-04-16/", "date": "2026-04-16", "summary": "Greenwood Capital Associates LLC significantly increased its stake in Danaher Corporation, boosting its holdings by 420.2% to 21,894 shares valued at $5.01 million in Q4. Danaher reported strong quarterly results, beating EPS expectations and increasing its dividend to $0.40 per share. Analysts generally rate DHR as a \"Moderate Buy\" with a consensus target price of $247.35, and institutional investors own approximately 79% of the company's shares.", "sentiment_score": 0.402652, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc stock (US00846U1016): Why its life sciences leadership matters more now for investors", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/agilent-technologies-inc-stock-us00846u1016-why-its-life-sciences/69167210", "date": "2026-04-15", "summary": "Agilent Technologies Inc. (US00846U1016) is highlighted as a resilient investment in the life sciences sector, providing essential analytical tools and services for drug discovery, clinical testing, and environmental monitoring. The article details its three key revenue segments—Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab—emphasizing the high-margin, recurring revenue from its services arm. Agilent's strong financial health, consistent free cash flow, and ex", "sentiment_score": 0.130601, "sentiment_label": "Neutral", "relevance_score": 0.596007, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Danaher Corporation Lowers Full-Year 2019 Outlook Despite Beating Earnings Expectations (NYSE:DHR)", "url": "https://www.stockinvestor.com/danaher-corporation-lowers-full-year-2019-outlook-despite-beating-earnings-expectations-nysedhr/amp/", "date": "2026-04-15", "summary": "Danaher Corporation (NYSE:DHR) beat analysts’ earnings expectations for the fifth consecutive quarter despite lowering its full-year 2019 outlook. While the share price saw a slight pullback due to the revised outlook, the company has shown steady asset appreciation over the past decade. Analysts remain largely optimistic about DHR's short-term future, with a significant upside potential to reach the average target price.", "sentiment_score": -0.208553, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.245, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "Danaher Corporation $DHR Shares Sold by Foster Victor Wealth Advisors LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-danaher-corporation-dhr-shares-sold-by-foster-victor-wealth-advisors-llc-2026-04-15/", "date": "2026-04-15", "summary": "Foster Victor Wealth Advisors LLC sold 11,742 shares of Danaher Corporation (DHR), reducing its stake by 12.8% to 79,914 shares valued at $18.86 million. Insider Gregory M. Milosevich also sold 1,320 shares for $274,573.20. Danaher recently beat earnings estimates, increased its quarterly dividend to $0.40, and received a \"Moderate Buy\" consensus rating from analysts, despite some recent price target adjustments.", "sentiment_score": 0.141924, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Danaher Corp. stock (US2358511028): Why does its business model matter more now for long-term invest", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/danaher-corp-stock-us2358511028-why-does-its-business-model-matter/69158449", "date": "2026-04-15", "summary": "Danaher Corp. (US2358511028) is highlighted as a compelling long-term investment due to its proven business model of acquiring, improving, and scaling high-quality companies in life sciences, diagnostics, and environmental solutions. The company's Danaher Business System (DBS) drives operational excellence and consistent margin expansion, supported by recurring revenue from consumables. This model, combined with strategic growth drivers like acquisitions in gene therapy and advanced diagnostics,", "sentiment_score": 0.491542, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Danaher Corp. stock (US2358511028): Why does its business model matter more now for long-term invest", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/danaher-corp-stock-us2358511028-why-does-its-business-model-matter/69158449", "date": "2026-04-15", "summary": "Danaher Corp. (US2358511028) is highlighted for its resilient business model driven by science-driven innovation and disciplined capital allocation in life sciences and diagnostics. The company's decentralized structure and Danaher Business System (DBS) ensure continuous improvement and consistent margin expansion, making it an attractive long-term investment for those seeking stability and growth in essential healthcare trends. Analysts view Danaher favorably due to its strong economic moat, re", "sentiment_score": 0.432147, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-04-17", "url": "https://www.sec.gov/Archives/edgar/data/313616/000119312526160383/0001193125-26-160383-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Dengue Testing Market Size to be Valued at USD 971.11 Million by 2035; Industry Growth is Driven by the Increase in Dengue Cases in Tropical and Sub-tropical Nations Globally | SNS Insider", "description": "Dengue testing market grows with rising cases, rapid diagnostics, RT-PCR adoption, and strong public health initiatives driving global demand....", "url": "https://www.globenewswire.com/news-release/2026/04/20/3276781/0/en/Dengue-Testing-Market-Size-to-be-Valued-at-USD-971-11-Million-by-2035-Industry-Growth-is-Driven-by-the-Increase-in-Dengue-Cases-in-Tropical-and-Sub-tropical-Nations-Globally-SNS-In.html", "date": "2026-04-20", "published_at": "2026-04-20T09:30:00Z", "sentiment": { "label": "positive", "score": 0.863, "confidence": 0.86 } }, { "source": "news", "source_name": "Weeklyosm.eu", "title": "weeklyOSM: weeklyOSM 821", "description": "09/04/2026-15/04/2026 [1] From Coordinates to Wall Art: Stylised Map Posters Online | © Yousuf Amanuel | map data © by OpenStreetMap Contributors. Mapping Comments are requested on this proposal: t…", "url": "https://weeklyosm.eu/archives/18529", "date": "2026-04-19", "published_at": "2026-04-19T10:59:18Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Barclays and Evercore Stay Positive on Danaher (DHR) Despite Cutting Price Targets", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_48209525-6804-4940-af25-355f1f5957fc", "date": "2026-04-18", "published_at": "2026-04-18T18:50:18Z", "sentiment": { "label": "positive", "score": 0.609, "confidence": 0.61 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Power Quality Meter Market Size to Hit USD 4.81 Billion by 2035 | SNS Insider", "description": "Power Quality Meter Market Size, Share, Trends & Segmentation, By Phase, By End-user, Technology, Application, Installation Type, Region, And Forecast 2035", "url": "https://www.globenewswire.com/news-release/2026/04/17/3276082/0/en/Power-Quality-Meter-Market-Size-to-Hit-USD-4-81-Billion-by-2035-SNS-Insider.html", "date": "2026-04-17", "published_at": "2026-04-17T11:30:00Z", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Just One Week Away. C-Level Technology Leadership and the Rise of Iconic Leaders Will Shape the Conversation at HMG Strategy’s 2026 Washington D.C. Summit. Be a Part of It. Register Now.", "description": "HMG Strategy’s D.C. Summit brings C-level tech leaders together April 21 to explore AI, security, and iconic leadership for 2030....", "url": "https://www.globenewswire.com/news-release/2026/04/15/3274661/0/en/Just-One-Week-Away-C-Level-Technology-Leadership-and-the-Rise-of-Iconic-Leaders-Will-Shape-the-Conversation-at-HMG-Strategy-s-2026-Washington-D-C-Summit-Be-a-Part-of-It-Register-No.html", "date": "2026-04-15", "published_at": "2026-04-15T14:57:00Z", "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Mastering DHF, DMR & DHR Course: Essential FDA Documentation for Medical Devices (ONLINE AND ON-DEMAND: May 14, 2026)", "description": "Opportunities lie in improving the management of DHF, DMR, and DHR for successful medical device manufacturing. This seminar will enhance understanding and compliance with FDA and EU regulations, focusing on technical documentation, safety standards, and audi…", "url": "https://www.globenewswire.com/news-release/2026/04/15/3274253/28124/en/Mastering-DHF-DMR-DHR-Course-Essential-FDA-Documentation-for-Medical-Devices-ONLINE-AND-ON-DEMAND-May-14-2026.html", "date": "2026-04-15", "published_at": "2026-04-15T10:07:00Z", "sentiment": { "label": "positive", "score": 0.9, "confidence": 0.9 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Rapid Diagnostic Tests Market Size is Expected to reach USD 67.83 Billion by 2035 Owing to the Increasing Number of Infections Globally | SNS Insider", "description": "Rapid diagnostic tests market grows with rising infections, home testing adoption, driven by tech advances, fast results, and expanding healthcare access....", "url": "https://www.globenewswire.com/news-release/2026/04/15/3274218/0/en/Rapid-Diagnostic-Tests-Market-Size-is-Expected-to-reach-USD-67-83-Billion-by-2035-Owing-to-the-Increasing-Number-of-Infections-Globally-SNS-Insider.html", "date": "2026-04-15", "published_at": "2026-04-15T09:30:00Z", "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Research and Global Forecast Report 2026-2035", "description": "The mRNA vaccine CDMO market is rapidly expanding, driven by growing biotech startups, limited in-house manufacturing, and increasing demand for rapid vaccine production in response to infectious diseases. Opportunities include personalized mRNA cancer vaccin…", "url": "https://www.globenewswire.com/news-release/2026/04/14/3273664/28124/en/Messenger-Ribo-Nucleic-Acid-mRNA-Vaccine-Contract-Development-and-Manufacturing-Organization-CDMO-Market-Research-and-Global-Forecast-Report-2026-2035.html", "date": "2026-04-14", "published_at": "2026-04-14T15:03:00Z", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Cell Line Development Market to Reach $8.95 Bn by 2031 with Gene & Cell Therapy Manufacturing Growing at 10.88% CAGR, Says Mordor Intelligence", "description": "Cell line development market driven by biologics, mAbs and gene therapies, with innovation and automation led by Thermo Fisher, Merck, Danaher, Lonza....", "url": "https://www.globenewswire.com/news-release/2026/04/14/3273032/0/en/Cell-Line-Development-Market-to-Reach-8-95-Bn-by-2031-with-Gene-Cell-Therapy-Manufacturing-Growing-at-10-88-CAGR-Says-Mordor-Intelligence.html", "date": "2026-04-14", "published_at": "2026-04-14T07:26:00Z", "sentiment": { "label": "positive", "score": 0.958, "confidence": 0.96 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider", "description": "Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies. Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies.", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272705/0/en/Companion-Diagnostics-Market-Size-is-Projected-to-Hit-USD-26-38-Billion-by-2035-SNS-Insider.html", "date": "2026-04-13", "published_at": "2026-04-13T15:30:00Z", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Allergy Diagnostic Market by Product & Service, Test Type, Allergen, End User - Global Forecast to 2031", "description": "The allergy diagnostic market is set to surge, projected to reach USD 10.77 billion by 2030 from USD 6.80 billion in 2025, at a CAGR of 9.6%. Technological innovation in diagnostics, such as multiplex immunoassays and molecular allergology, drives this growth…", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272461/28124/en/Allergy-Diagnostic-Market-by-Product-Service-Test-Type-Allergen-End-User-Global-Forecast-to-2031.html", "date": "2026-04-13", "published_at": "2026-04-13T12:00:00Z", "sentiment": { "label": "positive", "score": 0.602, "confidence": 0.6 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Cell Therapy Technology Market Research and Global Forecast Report 2025-2030: Rising Chronic Disease Burden and CRISPR-Driven Gene Editing Innovations Driving Growth", "description": "The global cell therapy technologies market is set to grow from USD 4.41 billion in 2025 to USD 7.91 billion by 2030, achieving a CAGR of 12.4%. Key growth drivers include advancements in regenerative medicine, increasing chronic disease prevalence, robust R&…", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272308/28124/en/Cell-Therapy-Technology-Market-Research-and-Global-Forecast-Report-2025-2030-Rising-Chronic-Disease-Burden-and-CRISPR-Driven-Gene-Editing-Innovations-Driving-Growth.html", "date": "2026-04-13", "published_at": "2026-04-13T10:11:00Z", "sentiment": { "label": "positive", "score": 0.772, "confidence": 0.77 } }, { "source": "news", "source_name": "The Tribune India", "title": "India launches first study on nutrition, supplements for adolescent athletes - The Tribune", "description": "Adolescents are particularly vulnerable due to their ongoing physical development and the risks associated with unsupervised supplement consumption, experts say.", "url": "https://www.tribuneindia.com/news/health/india-launches-first-study-on-nutrition-supplements-for-adolescent-athletes/", "date": "2026-04-12", "published_at": "2026-04-12T14:38:37Z", "sentiment": { "label": "negative", "score": -0.509, "confidence": 0.51 } }, { "source": "news", "source_name": "Weeklyosm.eu", "title": "weeklyOSM: weeklyOSM 820", "description": "02/04/2026-08/04/2026 [1] An assessment of neighbourhoods using OpenStreetMap data | © L_J_R | map data © by OpenStreetMap Contributors. Mapping Comments on the following proposal have been request…", "url": "https://weeklyosm.eu/archives/18506", "date": "2026-04-12", "published_at": "2026-04-12T11:53:19Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Independent.ie", "title": "Any Other Business: Fail to prepare, prepare to be well charged by a PR guru", "description": "DHR Communications may not have been entirely unhappy to see its name splashed across the front page of the newspapers last Tuesday, even in a report that Inland Fisheries Ireland had paid it €53,933 to have top brass coached in advance of their appearance be…", "url": "https://www.independent.ie/business/media/any-other-business-fail-to-prepare-prepare-to-be-well-charged-by-a-pr-guru/a1991351120.html", "date": "2026-04-12", "published_at": "2026-04-12T04:30:00Z", "sentiment": { "label": "negative", "score": -0.67, "confidence": 0.67 } }, { "source": "news", "source_name": "PR Newswire UK", "title": "Global Metabolomics Market Poised for Strong Growth as Advancements in Precision Medicine and Biomarker Discovery Accelerate Adoption: Verified Market Research®", "description": "The global metabolomics market is witnessing steady expansion driven by rising demand for precision medicine, biomarker discovery, and systems biology research. Technological advancements in mass spectrometry and nuclear magnetic resonance (NMR), coupled with…", "url": "https://www.prnewswire.co.uk/news-releases/global-metabolomics-market-poised-for-strong-growth-as-advancements-in-precision-medicine-and-biomarker-discovery-accelerate-adoption-verified-market-research-302739224.html", "date": "2026-04-10", "published_at": "2026-04-10T16:52:00Z", "sentiment": { "label": "positive", "score": 0.951, "confidence": 0.95 } }, { "source": "news", "source_name": "Techtarget.com", "title": "GenAI data center infrastructure reshapes business processes", "description": "Building and retrofitting data centers to support GenAI is not a matter of IF but WHEN, so the game plan must include power needs, grid connectivity, model training and permitting.", "url": "https://www.techtarget.com/searchenterpriseai/feature/GenAI-data-center-infrastructure-reshapes-business-processes", "date": "2026-04-10", "published_at": "2026-04-10T16:36:00Z", "sentiment": { "label": "positive", "score": 0.205, "confidence": 0.21 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - Asia-Pacific NGS Market Poised for Fastest Growth, Driven by Large-Scale Genomic Projects and the Rising Need for Precision Medicine", "description": "Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The \"Next-Generation Sequencing Market by Product Type, Technology, Workflow, Services, Application - Global Forecast to 2030\" has been added to ResearchAndMarkets.com's offering.The next-generation sequencing (NGS) …", "url": "https://www.globenewswire.com/news-release/2026/04/10/3271604/28124/en/Global-Next-Generation-Sequencing-NGS-Market-to-Double-in-Size-by-2030-Asia-Pacific-NGS-Market-Poised-for-Fastest-Growth-Driven-by-Large-Scale-Genomic-Projects-and-the-Rising-Need-.html", "date": "2026-04-10", "published_at": "2026-04-10T09:45:00Z", "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages", "description": "AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage\r\n: As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a…", "url": "https://www.globenewswire.com/news-release/2026/04/09/3270963/0/en/AI-Powered-Pharma-Manufacturing-Signals-Scalable-Efficiency-Long-Term-Cost-Advantages.html", "date": "2026-04-09", "published_at": "2026-04-09T12:30:00Z", "sentiment": { "label": "positive", "score": 0.751, "confidence": 0.75 } }, { "source": "news", "source_name": "Bikerumor.com", "title": "All New Liv Embolden Gets All the Right Updates for an Affordable Modern Trail", "description": "Liv's Embolden trail bike was a great option for ladies looking to get into the sport; however, the geo was a bit outdated...well, not anymore\nThe post All New Liv Embolden Gets All the Right Updates for an Affordable Modern Trail appeared first on Bikerumor.", "url": "https://bikerumor.com/liv-makes-necessary-updates-to-the-embolden-for-a-more-modern-trail-bike-at-a-good-price/", "date": "2026-04-08", "published_at": "2026-04-08T16:00:00Z", "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Flow Cytometry Market Set to Surpass USD 12.19 Billion by 2035, Driven by Rising Demand for Precision Diagnostics – SNS Insider", "description": "Austin, United States, April 08, 2026 (GLOBE NEWSWIRE) -- SNS Insider reported that global Flow Cytometry Market was valued at USD 5.75 billion in 2025 and is expected to reach USD 12.19 billion by 2035, growing at a CAGR of 7.8% over the forecast period of 2…", "url": "https://www.globenewswire.com/news-release/2026/04/08/3270347/0/en/Flow-Cytometry-Market-Set-to-Surpass-USD-12-19-Billion-by-2035-Driven-by-Rising-Demand-for-Precision-Diagnostics-SNS-Insider.html", "date": "2026-04-08", "published_at": "2026-04-08T15:33:00Z", "sentiment": { "label": "positive", "score": 0.718, "confidence": 0.72 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Evercore ISI Cuts Danaher (DHR) Price Target, Adds Shares to Tactical Outperform List", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_c083ef15-d8fa-49c0-8b46-02592de8029a", "date": "2026-04-08", "published_at": "2026-04-08T04:14:38Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Purvalanol A (CDK Inhibitor) Market Report 2026: Expanding Molecular Biology and Cancer Research Fuelling Market Growth", "description": "Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The \"Purvalanol A (CDK Inhibitor) Market Report 2026\" has been added to ResearchAndMarkets.com's offering. ...", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269499/28124/en/Purvalanol-A-CDK-Inhibitor-Market-Report-2026-Expanding-Molecular-Biology-and-Cancer-Research-Fuelling-Market-Growth.html", "date": "2026-04-07", "published_at": "2026-04-07T16:13:00Z", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global Biopreservation Market Analysis by Product Type, Application, End User, and Region, 2025-2035: Cell and Gene Therapies Drive Biopreservation Demand", "description": "Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The \"Biopreservation Market - A Global and Regional Analysis: Product Type, Application, End User, and Regional Analysis - Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269491/28124/en/Global-Biopreservation-Market-Analysis-by-Product-Type-Application-End-User-and-Region-2025-2035-Cell-and-Gene-Therapies-Drive-Biopreservation-Demand.html", "date": "2026-04-07", "published_at": "2026-04-07T16:04:00Z", "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "news", "source_name": "The Irish Times", "title": "Fisheries agency spent about €60,000 on communications training prior to PAC appearance", "description": "Payment represented ‘extraordinary unjustifiable use of public money’", "url": "https://www.irishtimes.com/politics/2026/04/07/fisheries-agency-spent-about-60000-on-communications-training-prior-to-pac-appearance/", "date": "2026-04-07", "published_at": "2026-04-07T05:00:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Membrane Filters Market Size to Surpass USD 30.21 Billion by 2035 | SNS Insider", "description": "The Membrane Filters Market is expanding as demand grows across water treatment and life sciences, with the U.S. segment increasing from USD 4.61 billion in 2025 to USD 11.03 billion by 2035 amid regulatory and industrial growth. The Membrane Filters Market i…", "url": "https://www.globenewswire.com/news-release/2026/04/06/3268318/0/en/Membrane-Filters-Market-Size-to-Surpass-USD-30-21-Billion-by-2035-SNS-Insider.html", "date": "2026-04-06", "published_at": "2026-04-06T10:30:00Z", "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider", "description": "Molecular diagnostics market to grow from $18.26 Bn to $43.50 Bn by 2035, driven by PCR, NGS, and demand for early, precise diagnosis....", "url": "https://www.globenewswire.com/news-release/2026/04/03/3267957/0/en/Molecular-Diagnostics-Market-Size-is-Expected-to-Reach-USD-43-50-Billion-by-2035-Owing-to-the-Surging-Demand-for-Accurate-and-Early-Disease-Detection-Globally-SNS-Insider.html", "date": "2026-04-03", "published_at": "2026-04-03T09:00:00Z", "sentiment": { "label": "negative", "score": -0.226, "confidence": 0.23 } }, { "source": "news", "source_name": "Inside Higher Ed", "title": "What May (or May Not) Get University Employees Fired", "description": "What May (or May Not) Get University Employees Fired\n\nkjohnsonbowles…\n\nFri, 04/03/2026 - 03:00 AM\n\nStories of performance and behavioral issues abound in higher education. From a list of scenarios, could you guess how many ended with someone being fired?\n \n B…", "url": "https://www.insidehighered.com/opinion/columns/just-explain-it-me/2026/04/03/why-accountability-inconsistently-enforced", "date": "2026-04-03", "published_at": "2026-04-03T07:00:00Z", "sentiment": { "label": "negative", "score": -0.896, "confidence": 0.9 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "[Latest] Global Environmental Mass Spectrometry Market Size/Share Worth USD 6.47 Billion by 2035 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)", "description": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Environmental Mass Spectrometry Market size & share revenue was valued at approximately USD 2.84 Billion in 2025 and is expected…", "url": "https://www.globenewswire.com/news-release/2026/04/02/3267246/0/en/Latest-Global-Environmental-Mass-Spectrometry-Market-Size-Share-Worth-USD-6-47-Billion-by-2035-at-a-7-6-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-.html", "date": "2026-04-02", "published_at": "2026-04-02T11:30:00Z", "sentiment": { "label": "positive", "score": 0.859, "confidence": 0.86 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Antimicrobial Resistance Surveillance Market Set to Reach USD 11.17 Billion by 2035 – SNS Insider", "description": "Rising prevalence of drug-resistant infections and government-led monitoring initiatives drive a steady 5.47% CAGR through 2035. Rising prevalence of drug-resistant infections and government-led monitoring initiatives drive a steady 5.47% CAGR through 2035.", "url": "https://www.globenewswire.com/news-release/2026/04/02/3267148/0/en/Antimicrobial-Resistance-Surveillance-Market-Set-to-Reach-USD-11-17-Billion-by-2035-SNS-Insider.html", "date": "2026-04-02", "published_at": "2026-04-02T08:30:00Z", "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Wilms Tumor Protein Market Outlook 2026-2030 and 2035 Shows 6.9% CAGR as Rising Investment in Oncology Research Accelerates Industry Growth", "description": "Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The \"Wilms Tumor Protein Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, covering market statistics, regional shares, competitor data, market seg…", "url": "https://www.globenewswire.com/news-release/2026/03/31/3265766/28124/en/Wilms-Tumor-Protein-Market-Outlook-2026-2030-and-2035-Shows-6-9-CAGR-as-Rising-Investment-in-Oncology-Research-Accelerates-Industry-Growth.html", "date": "2026-03-31", "published_at": "2026-03-31T15:07:00Z", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "news", "source_name": "Bikerumor.com", "title": "Mondraker Leaves Something to the Imagination with Early Tease of Avinox-Powered ZENDIT eMTB", "description": "In a cheeky move by Mondraker, they’ve revealed almost everything about their new ZENDIT eMTB, except for the motor specs.\nThe post Mondraker Leaves Something to the Imagination with Early Tease of Avinox-Powered ZENDIT eMTB appeared first on Bikerumor.", "url": "https://bikerumor.com/mondraker-leaves-something-to-the-imagination-with-early-tease-of-avinox-powered-zendit-emtb/", "date": "2026-03-27", "published_at": "2026-03-27T19:52:32Z", "sentiment": { "label": "negative", "score": -0.557, "confidence": 0.56 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Danaher (DHR) Projects 2026 Revenue Growth at TD Cowen 46th Annual Health Care Conference", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_1f8a8b1e-8c4c-490c-a5cd-c476afe69798", "date": "2026-03-24", "published_at": "2026-03-24T14:43:04Z", "sentiment": { "label": "positive", "score": 0.9, "confidence": 0.9 } }, { "source": "pubmed", "pmid": "41951782", "title": "Reproductive hormone stability with prolonged intranasal oxytocin in adults with obesity.", "authors": "Galbiati F et al.", "journal": "International journal of obesity (2005)", "date": "2026 Apr 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41951782/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41944812", "title": "Toward actionable interventions in human aging (12th ARDD meeting, 2025).", "authors": "Dekan A et al.", "journal": "Aging", "date": "2026 Apr 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41944812/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41933068", "title": "Longer duration of amenorrhea is associated with lower delay discounting and less hedonic eating in girls and young women with low-weight eating disorders.", "authors": "Wronski ML et al.", "journal": "Scientific reports", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933068/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } } ] } }